Congenital heart diseaseCohort study
Transcatheter Patent Ductus Arteriosus Closure in Extremely Premature Infants
- Retrospective cohort study
- single-group review in 3 phases
Authors' conclusion
Bedside TCPC is a feasible, safe, and effective approach for managing PDA in extremely premature infants.
Study context
- Population
- Infants at <28 weeks' gestation weighing <2 kg with hemodynamically significant patent ductus arteriosus (PDA) undergoing transcatheter PDA closure (TCPC), July 2012 to December 2024
- Participants
- 500 infants
- Exposure
- Bedside TCPC in the neonatal intensive care unit (NICU) vs laboratory-based TCPC
- Bedsiden = 176
Main finding
As reported in the abstract
Procedural outcomes
| Group | Procedure duration | Radiation exposure |
|---|---|---|
| Bedside | 18 minutes | 0.019 Gy × cm² |
| Laboratory | 32 minutes | 0.068 Gy × cm² |
- Bedside vs Laboratory: P < 0.001 — radiation exposure
- Procedural success across all settings
- 100%
Observational data: associations, not effects.
Further findings
| Outcome | Bedside | Laboratory |
|---|---|---|
| Procedure duration and radiation exposure | ||
| Procedure duration | 18 minutes | 32 minutes |
| Radiation exposure | 0.019 Gy × cm² | 0.068 Gy × cm² |
- Procedure duration and radiation exposure: radiation exposure P < 0.001
Long-term follow-up · median 6.8 years
- Survival
- 89%
- No residual PDAs
- Minimal late complications
Safety
Major complications
- Major complication rate, similar across settings
- 1.7%
Original publication
Transcatheter Patent Ductus Arteriosus Closure in Extremely Premature Infants. JACC Cardiovasc Interv. Published 28 September 2026. doi:10.1016/j.jcin.2026.05.040
Summarised from the published abstract; every number is checked against it